Option chain shows key data for Medivolve's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Medivolve.

Medivolve (OTC:MEDVF) Stock, Option Chain

Medivolve Inc is a healthcare technology and services company. It is engaged in finding and developing disruptive technologies, groundbreaking innovations, and partnerships to help combat COVID-19 and transform human health management. The company operated one reportable segment, the COVID Testing facilities across the United States Of America.

Medivolve Inc

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and maintains $36 price target.

News

Price Target

Reiteration

Analyst Ratings

FDMT

HC Wainwright & Co. Reiterates Buy on 4D Molecular Therapeutics, Maintains $36 Price Target

Jefferies analyst Lloyd Byrne initiates coverage on Flowco Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLOC#NYSE">FLOC</a>) with a Buy rating and announces Price Target of $35.

Initiation

FLOC

Jefferies Initiates Coverage On Flowco Holdings with Buy Rating, Announces Price Target of $35

Guidance

Spirit AeroSystems Expects Future Free Cash Flow Usage For Q1, Q2 2025  To Be $650M - $700M

Needham analyst Joseph Stringer maintains Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) with a Buy and lowers the price target from $38 to $10.

PLRX

Needham Maintains Buy on Pliant Therapeutics, Lowers Price Target to $10

Needham analyst Ryan Koontz reiterates Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) with a Buy and maintains $19 price target.

VSAT

Needham Reiterates Buy on Viasat, Maintains $19 Price Target

Up to €15 billion of data center investment will be led by Brookfield's portfolio company, Data4, one of Europe's largest data center developers, headquartered in Paris.&nbsp;
Data4 has existing plans to build over 500 MW of data center capacity located across several regions in France, with an ambition to triple that by 2030 as part of today's announcement. With this, France is projected to be the single largest market for Data4 in Europe.

Brookfield Asset Management Reveals €20B Infrastructure Investment Program To Support  Deployment Of AI Infrastructure In France

DA Davidson analyst Brian Holland maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $164 to $149.

DA Davidson Maintains Neutral on Hershey, Lowers Price Target to $149

Management

Cemex CEO Fernando González Decides To Retire; Jaime Muguiro Appointed As New CEO, Effective April 1, 2025

Spirit AeroSystems Expects Continued Operational Environment And Higher Delivery Rates To Drive Better Results In 2025

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRBP#NASDAQ">CRBP</a>) with a Buy and lowers the price target from $80 to $75.

CRBP

HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Lowers Price Target to $75

Canaccord Genuity analyst Brian McNamara maintains Newell Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) with a Buy and lowers the price target from $15 to $14.

Canaccord Genuity Maintains Buy on Newell Brands, Lowers Price Target to $14

Revenue decreased from the fourth quarter of 2023, primarily due to the impacts from the Boeing Memorandum of Agreement (MOA) executed in October&nbsp;2023 recognized in the fourth quarter of 2023, including favorable pricing adjustments on the Boeing 787 program and the reversal of the potential claim related to the Boeing 737 vertical fin attach fittings issue, partially offset by higher Defense and Space revenues in the fourth quarter of 2024.&nbsp;
Overall deliveries increased during the fourth quarter of 2024 compared to the same period of 2023, including higher Boeing 737 deliveries.
Gross loss was recognized in the fourth quarter of 2024 compared to gross profit for the same period of 2023. The operating income recognized in the fourth quarter of 2023 included the favorable impact of the Boeing MOA executed in October&nbsp;2023 to the Boeing 787 program, including favorable change in estimates as well as a material right obligation liability reversal.

Spirit AeroSystems Says Merger With Boeing On Track To Close In Mid-2025

Spirit AeroSystems Q4 Preliminary Net Revenues $1.662B Vs $1.813B Last Year; Est $1.614B

HC Wainwright &amp; Co. analyst Ed Arce downgrades Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Neutral.

Downgrades

HC Wainwright & Co. Downgrades Pliant Therapeutics to Neutral

Bozeman has served as President and Chief Executive Officer, and a director, of C.H. Robinson since 2023.&nbsp;

3M Adds David Bozeman To Board, Amy Hood Does Not Intend To Stand For Reelection

Michael F. Roman, Executive Chairman of the Board of Directors, has announced his intention to retire as Executive Chairman, and as a Director, effective March 1, 2025.&nbsp; Mr. Roman has agreed to continue to serve as Executive Advisor to the Board until his retirement from 3M on May 1, 2025.&nbsp;

3M Names William Brown, Its CEO And Director, To Serve As Its Chairman, Effective March 1, 2025 In Addition To His Current Responsibilities

SPACE

Contracts

General

GSAT

MDA Space Has Signed A Definitive Contract With Globalstar To Be The Prime Contractor For The Satellite Operator's Next-Generation Low Earth Orbit Constellation, With A Total Contract Value Of Approximately $1.1B

Ancora Issues Letter To US Steel's Board; Says Independent Slate and Alan Kestenbaum Are Ready to Lead Multibillion-Dollar Capital Investment Program to Revitalize Company

TRX Gold Secures New Financing Agreements With Stanbic And Auramet To Boost Liquidity, Expand Growth Opportunities

Needham analyst Mike Cikos reiterates Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) from Hold to Hold.

Comments

Medivolve

Medivolve (MEDVF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga